Generation of recombinant antibodies against human tissue kallikrein 7 to treat skin diseases.
Antibody
Enzyme inhibitor
Kallikrein
Phage display
Protease
Skin disease
scFv
scFv-Fc
Journal
Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
06
07
2020
revised:
09
10
2020
accepted:
14
10
2020
pubmed:
24
10
2020
medline:
3
7
2021
entrez:
23
10
2020
Statut:
ppublish
Résumé
Human tissue kallikreins (KLKs) constitute a family of 15 serine proteases that are distributed in various tissues and implicated in several pathological disorders. KLK7 is an unusual serine protease that presents both trypsin-like and chymotrypsin-like specificity and appears to be upregulated in pathologies that are related to skin desquamation processes, such as atopic dermatitis, psoriasis and Netherton syndrome. In recent years, various groups have worked to develop specific inhibitors for this enzyme, as KLK7 represents a potential target for new therapeutic procedures for diseases related to skin desquamation processes. In this work, we selected nine different single-chain variable fragment antibodies (scFv) from a human naïve phage display library and characterized their inhibitory activities against KLK7. The scFv with the lowest IC
Identifiants
pubmed: 33096161
pii: S0960-894X(20)30737-X
doi: 10.1016/j.bmcl.2020.127626
pii:
doi:
Substances chimiques
Recombinant Proteins
0
Serine Proteinase Inhibitors
0
Single-Chain Antibodies
0
KLK7 protein, human
EC 3.4.21.-
Kallikreins
EC 3.4.21.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
127626Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.